Clinical trial
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage…
NCT00083941 · Oxford BioMedica, Industry · Completed
Key facts
| NCT number | NCT00083941 |
|---|---|
| Title | A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer |
| Official title | Clinical Trial Phase II (Single Centre Study) : A Preliminary Study of the Safety, Immunogenicity, and Clinical Efficacy of TroVax Given in Conjunction With Interleukin 2 (IL-2) in the Treatment of Stage IV Renal Cell Cancer |
| Lead sponsor | Oxford BioMedica, Industry |
| Collaborators | Columbia University ORION Clinical Services Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Biological |
| Interventions | TroVax, Interleukin-2 |
| Enrollment | 25 |
| Start date | Aug 1, 2004 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Jun 7, 2004 |
| Last update posted | Oct 19, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: